Crohn's disease and Escherichia coli: A new approach in therapy to maintain remission of colonic crohn's disease?

Journal of Clinical Gastroenterology

Volumn 25, Issue 4, 1997, Pages 653-658

  Malchow, Helmut A ^a  

^a KLINIKUM LEVERKUSEN   (Germany)

Author keywords

Crohn's disease; Glucocorticosteroids; Intestinal microflora; Therapeutic Escherichia coli

Indexed keywords

PREDNISOLONE;

ADULT; ANTIGEN ANTIBODY COMPLEX; ANTIINFLAMMATORY ACTIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; COLITIS; CONTROLLED STUDY; CROHN DISEASE; DOUBLE BLIND PROCEDURE; ESCHERICHIA COLI; GENETIC PREDISPOSITION; HUMAN; IMMUNE RESPONSE; PATHOGENICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; REVIEW;

BIOLOGICAL THERAPY; COLITIS; CROHN DISEASE; DOUBLE-BLIND METHOD; ESCHERICHIA COLI; HUMANS; INTESTINES; PILOT PROJECTS; PREDNISOLONE; TREATMENT OUTCOME;

EID: 0031443860     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-199712000-00021     Document Type: Review

References (55)

1. Rotter JI. Immunogenetic susceptibility in IBD. In: Williams CN, ed. Trends in Inflammatory Bowel Disease Therapy. Dordrecht: Kluwer Academic Publishers;1991:1-9.
2. Sartor RB. Role of the intestinal microflora in pathogenesis and complications. In: Schölmerich J, Kruis W, Goebell H, Hohenberger W, Gross V, eds. Inflammatory Bowel Diseases - Pathophysiology as Basis of Treatment. Dordrecht: Kluwer Academic Publishers; 1993:175-87.
3. Shanahan F. Pathogenesis of ulcerative colitis. Lancet 1993;342: 407-11.
4. Gorbach SL. Intestinal microflora in inflammatory bowel disease - implication for etiology. In: Kirsner J, Shorter R, eds. Inflammatory Bowel Disease. Philadelphia: Lea & Febiger; 1988: 51-64.
5. Sartor RB. The role of intestinal microflora in initiation and perpetuation of inflammatory bowel disease. In: Williams CN, ed. Trends in Inflammatory Bowel Disease. Dordrecht: Kluwer Academic Publishers; 1991:17-27.
6. von Wulffen H, Russmann H, Karch H, et al. Verocytotoxin producing Escherichia coli 02:H5 isolated from patients with ulcerative colitis. Lancet 1989;i:1449-50.
7. Ljungh A, Eriksson M, Eriksson Ö, Henter JI, Wadström T. Shiga-like toxin production and connective tissue protein binding of Escherichia coli isolated from a patient with ulcerative colitis. Scand J Infect Dis 1988;20:443-6.
8. Kangro HO, Chong SKF, Hardiman A, Heath RB, Walker-Smith JA. A prospective study of viral and mycoplasma infections in chronic inflammatory bowel disease. Gastroenterology 1990;98: 549-53.
9. Sartor RB. Role of intestinal microflora in initiation and perpetuation of inflammatory bowel disease. Can J Gastroenterol 1990;4:271-7.
10. Clausen MR, Tvede M, Mortensen PB. Short-chain fatty acids in pouch contents from patients with and without pouchitis after ileal pouch-anal anastomosis. Gastroenterology 1992;103:1144-53.
11. Hang JM, Soergel KH, Komorowski RA, Wood CM. Treatment of diversion colitis with short-chain-fatty acid irrigation. N Engl J Med 1989;320:23-8.
12. Mortensen PB, Clausen MR. Short-chain fatty acids in the human colon: relation to gastrointestinal health an disease. Scand J Gastroenterol 1996;216(Suppl):132-18.
13. LeDuc LE, Nast CC. Chemotactic peptide-induced acute colitis in rabbits. Gastroenterology 1990;98:929-35.
14. von Ritter C, Sekizuka E, Grisham MB, Granger DN. The chemotactic peptide N-formyl-methionyl-leucyl-phenylalanine increases mucosal permeability in the distal ileum of the rat. Gastroenterology 1988;95:651-6.
15. Severijnen AJ, van Kleef R, Hazenberg MP, van de Merwe JP. Chronic arthritis induced in rats by cell wall fragments of Eubacterium species from the human intestinal flora. Infect Immunol 1990;58:523-8.
16. Isgar B, Harmann M, Whorwell PJ. Factors preceding relapse of ulcerative colitis. Digestion 1983;26:236-8.
17. Saverymuttu S, Hodgson HJF, Chadwick VA. Controlled trial comparing prednisolone with an elemental diet plus non-absorbable antibiotics in active Crohn's disease. Gut 1985;26:994-8.
18. Bennet JD, Brinkmann M. Treatment of ulcerative colitis by implantation of normal colonic flora. Lancet 1989;i:164.
19. Borody TJ, George L, Andrews P, et al. Bowel-flora alteration: a potential cure for inflammatory bowel disease and irritable bowel syndrome? Med J Aust 1989;150:604.
20. Doman DB, Golding MI, Goldberg HJ, Doyle RB. Aeromonas hydrophila colitis presenting as medically refractory inflammatory bowel disease. Am J Gastroenterol 1989;84:136-7.
21. Taylor-Robinson S, Miles R, Whitehead A, Dickinson RJ. Salmonella infection and ulcerative colitis. Lancet 1989;i:1145.
22. Chiodini RJ. Crohn's disease and the mycobacterioses: a review and comparision of two disease entities. Clin Microbiol Rev 1989; 2:90-117.
23. Liu Y, Van Kruiningen HJ, West AB, et al. Immunocytochemical evidence of Listeria, Escherichia coli, and Streptococcus antigens in Crohn's disease. Gastroenterology 1995;108:1396-404.
24. Cooke EM, Ewins SP, Hywel-Jones J, Lennart-Jones JE. Properties of strains of Escherichia coli carried in different phases of ulcerative colitis. Gut 1974;15:143-6.
25. Shorter RG, Cardosa MR, ReMine SG, Spencer RJ, Huizenga KA. Modification of in vitro cytotoxicity of lymphocytes from patients with ulcerative colitis or granulomatous colitis for allogenic colonic epithelial cells. Gastroenterology 1970;58:143-6.
26. Lowes JR, Jewell DP. The immunology of inflammatory bowel disease. Springer Semin Immunopathol 1990;12:251-68.
27. Burke DA, Axon ATR. Ulcerative colitis and Escherichia coli with adhesive properties. J Clin Pathol 1987;40:782-6.
28. Burke DA, Axon ATR. Adhesive Escherichia coli in inflammatory bowel disease and infective diarrhoea. BMJ 1988;297:102-4.
29. Burke DA, Axon ATR. Hydrophobic adhesion of E. coli in ulcerative colitis. Gut 1988;29:41-3.
30. Giaffer MH, Holdsworth CD, Duerden BI. Virulence properties of Escherichia coli strains isolated from patients with inflammatory bowel disease. Gut 1992;33:646-50.
31. Burke DA, Axon ATR, Clayden SA, et al. The efficacy of tobramycin in the treatment of ulcerative colitis. Aliment Pharmacol Therap 1990;4:123-9.
32. Lobo AJ, Burke DA, Sobala GM, Axon ATR. Oral tobramycin in ulcerative colitis: effect on maintenance of remission. Alim Pharmacol Therap 1993;7:155-8.
33. Kruis W, Stolte M, Fixa B, Fric P, Judmaier G. Double-blind comparision between mesalamine (Salofalk) and a preparation of viable E. coli Nissle 1917 (Mutaflor) for maintenance therapy of ulcerative colitis. Gastroenterology 1995;108(Suppl):A853.
34. Kruis W, Schütz E, Fric P, et al. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Therap (in press).
35. Malchow H, Sonnenborn U, Greinwald R, Körner A. Colonization of adults by a non-pathogenic Escherichia coli strain. Gastroenterology 1995;108(Suppl):A869.
36. Sonnenborn U, Greinwald R. Beziehungen zwischen Wirtsorganismus und Darmflora. Stuttgart: Schattauer Verlagsgesellschaft; 1991:55-68.
37. Best WR, Becktel JM, Singleton JW, Kern F. Development of Crohn's disease activity index. National Cooperative Crohn's disease study. Gastroenterology 1976;70:439-44.
38. Wellmann W, Fink PC, Schmidt FW. Whole-gut irrigation as antiendotoxinaemic therapy in inflammatory bowel disease. Hepato-gastroenterol 1984;31:91-3.
39. Wellmann W, Fink PC, Benner F, Schmidt FW. Endotoxaemia in active Crohn's disease. Treatment with whole gut irrigation and 5-aminosalicylic acid. Gut 1986;27:814-20.
40. Lennard-Jones JE. Future treatments: facts, hopes and fantasies. In: Schölmerich J, Kruis W, Goebell H, Hohenberger W, Gross V, eds. Inflammatory Bowel Diseases - Pathophysiology as Basis of Treatment. Dordrecht: Kluwer Academic Publishers;1993:466-76.
41. Prantera C, Kohn A, Mangiarotti R, Andreoli A, Luzi C. Antimycobacterial therapy in Crohn's disease: results of a controlled, double-blind trial with a multiple antibiotic regimen. Am J Gastroenterol 1994;89:513-8.
42. Prantera C, Zannoni F, Scribano ML, et al. An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazol plus ciprofloxacin. Am J Gastroenterol 1996;91:328-32.
43. Shah SA, Peppercorn MA. Inflammatory bowel disease therapy: an update. Compr Ther 1995;21:296-302.
44. Linn FV, Pepercorn MA. Drug therapy for inflammatory bowel disease. Am J Surg 1992;164:178-85.
45. Peppercorn MA. Is there a role for antibiotics as primary therapy in Crohn's ileitis? J Clin Gastroenterol 1993;17:235-7.
46. Cartun RW, Van Kruiningen HJ, Pedersen CA, Berman MM. An immunocytochemical search for infectious agents in Crohn's disease. Mod Pathol 1993;6:212-9.
47. Van Kruiningen HJ. On the use of antibiotics in Crohn's disease. J Clin Gastroenterol 1995;20:310-6.
48. Duchmann R, Kaiser I, Hermann E, et al. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 1995;102:448-55.
49. Tvede M, Rask-Madsen J. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet 1989;i: 1156-60.
50. McCann ML, Greinwald R, Sonnenborn U, Nelson R, Good R. Longlasting remissions of inflammatory bowel disease produced by sustained colonization with non-pathogenic E. coli. J Allergy Clin Immunol 1992;89:290.
51. McCann ML, Abrams RS, Nelson RP. Recolonization therapy with nonadhesive Escherichia coli for treatment of inflammatory bowel disease. Ann NY Acad Sci 1994;730:243-5.
52. International Mesalazine Study Group. Coated oral 5-aminosalicylic acid versus placebo in maintaining remission of inactive Crohn's disease. Aliment Pharmacol Therap 1990;4: 55-64.
53. Del Corso L, Moruzzo D, Romanelli AM, et al. 5-Aminosalicylsäure in der Rezidivprophylaxe des Morbus Crohn. Dtsch Med Wschr 1995;120:1723-7.
54. Belluzzi A, Brignola C, Campieri M, et al. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. N Engl J Med 1996;334:1557-60.
55. Fraser GM, Niv Y. Six patients whose perianal and ileocolic Crohn's disease improved in the Dead Sea environment. J Clin Gastroenterol 1995;21:217-9.